Agile Therapeutics, Inc. (AGRX)

NASDAQ: AGRX · IEX Real-Time Price · USD
0.189
-0.001 (-0.63%)
At close: Dec 9, 2022 4:00 PM
0.185
-0.004 (-1.96%)
After-hours: Dec 9, 2022 5:38 PM EST
-0.63%
Market Cap 7.72M
Revenue (ttm) 8.40M
Net Income (ttm) -67.01M
Shares Out 37.00M
EPS (ttm) -26.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 321,028
Open 0.19
Previous Close 0.19
Day's Range 0.182 - 0.192
52-Week Range 0.183 - 27.6
Beta 1.15
Analysts Buy
Price Target 3.06 (+1,520.8%)
Earnings Date Nov 7, 2022

About AGRX

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen ... [Read more]

Industry Pharmaceuticals
IPO Date May 23, 2014
CEO Alfred Altomari
Employees 30
Stock Exchange NASDAQ
Ticker Symbol AGRX
Full Company Profile

Financial Performance

In 2021, AGRX's revenue was $4.10 million, an increase of 447.53% compared to the previous year's $749,000. Losses were -$74.89 million, 44.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for AGRX stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 1,520.76% from the latest price.

Price Target
$3.06
(1,520.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference

PRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth Co...

1 week ago - GlobeNewsWire

Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Net Revenue Increased 43% from Second Quarter 2022

1 month ago - GlobeNewsWire

Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, ...

Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET

1 month ago - GlobeNewsWire

Agile Therapeutics Announces Reorganization of Leadership Team

Appointment of Amy Welsh to Chief Commercial Officer Prioritizes Commercial Growth

2 months ago - GlobeNewsWire

Agile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PRINCETON, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Chairman and Chief Executive Officer Al Altomari and Vice Presid...

3 months ago - GlobeNewsWire

Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11...

Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET

4 months ago - GlobeNewsWire

Agile Therapeutics Updates Second Quarter 2022 Guidance

Twirla® Demand Guidance (Total Cycles) Expected to be at Midpoint of Guided Range

4 months ago - GlobeNewsWire

Agile Therapeutics to Participate in Maxim Group's Upcoming Women's Health Panel

PRINCETON, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be participating in a vir...

5 months ago - GlobeNewsWire

Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering

PRINCETON, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its previ...

5 months ago - GlobeNewsWire

Agile Therapeutics Announces Pricing of $24 Million Upsized Public Offering

PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the pricing of its upsiz...

5 months ago - GlobeNewsWire

Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference

PRINCETON, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will present at...

6 months ago - GlobeNewsWire

Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation

PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today publicly released the findings of its first year of post-marketing pharmaco...

7 months ago - GlobeNewsWire

Agile Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on Thursday, May 12, 2022

Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET

7 months ago - GlobeNewsWire

Agile Therapeutics Announces 1-For-40 Reverse Stock Split

PRINCETON, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that the Board approved a 1-for-40 reverse stock spli...

7 months ago - GlobeNewsWire

Agile Therapeutics Announces First Quarter 2022 Prescription Data for Twirla®

29% increase in Twirla cycles 27% increase in total prescriptions (TRx) of Twirla

7 months ago - GlobeNewsWire

Agile Therapeutics Receives $4.7M After Selling Net Operating Loss Tax Benefits Through New Jersey Economic Developme...

PRINCETON, N.J., April 11, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the receipt of $4.7 million in net proceeds from the sale of ta...

7 months ago - GlobeNewsWire

Agile Therapeutics® Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American ...

The abstract was accepted by ACOG and will be presented from May 4th – May 6th, 2022 The abstract was accepted by ACOG and will be presented from May 4th – May 6th, 2022

8 months ago - GlobeNewsWire

Agile Therapeutics® Announces First Twirla® Commercial Targeting Gen Z

Partners with Award-Winning Director Maya Albanese

8 months ago - GlobeNewsWire

Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of -17.65% and 3.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Agile Therapeutics Reports Fourth Quarter & Full Year 2021 Financial Results and Provides Corporate Update

Twirla Demand Grows with Cycles Dispensed and Total Prescriptions (TRx) Up 35% and 33% Respectively in Fourth Quarter 2021 vs Third Quarter 2021

8 months ago - GlobeNewsWire

Agile Therapeutics Announces Closing of $4.85 Million Registered Direct Offering

PRINCETON, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that it has closed its ...

8 months ago - GlobeNewsWire

Agile Therapeutics to Participate in Upcoming March Investor Events

PRINCETON, N.J., March 11, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will part...

8 months ago - GlobeNewsWire

Agile Therapeutics to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide Corporate ...

Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET

9 months ago - GlobeNewsWire

Agile Therapeutics Acknowledges New Government Guidance Reinforcing Requirement to Cover Contraceptives that a Woman ...

PRINCETON, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- On January 10, 2022, the tri-agencies, Department of Labor (DOL), Health and Human Services (HHS) and Treasury issued new guidance that supports women'...

10 months ago - GlobeNewsWire

Agile Therapeutics and Afaxys Partner to Expand Access to Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal ...

PRINCETON, N.J. and CHARLESTON, S.C., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced a new alliance with Afaxys Pharma, LLC to p...

10 months ago - GlobeNewsWire